Form 4: Replimune CEO Granted 200,000 RSUs

Replimune Group, Inc. CEO Sushil Patel was granted 200,000 restricted stock units, vesting over two years.

Summary

• Sushil Patel, Chief Executive Officer and Director of Replimune Group, Inc., was granted 200,000 shares of common stock.
• These shares represent Restricted Stock Units (RSUs) with a transaction price of $0.
• Following this transaction, Patel beneficially owns 533,576 shares.
• The RSUs will vest in two equal tranches: 50% on November 15, 2026, and the remaining 50% on November 15, 2027.
• Vesting is contingent upon Patel's continuous service to the Issuer.

Sentiment

Score: 7

Explanation: The grant of RSUs to the CEO is a positive for management alignment and retention, indicating continued commitment. It's a standard compensation event, not directly impacting operational performance, hence a moderately positive score.

Positives

• The grant of 200,000 Restricted Stock Units (RSUs) to CEO Sushil Patel aligns management interests with shareholder value.
• The vesting schedule over two years (50% on November 15, 2026, and 50% on November 15, 2027) incentivizes long-term commitment and performance.

Negatives

• No explicit negatives are detailed in this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing.

Future Outlook

The grant of Restricted Stock Units with a vesting schedule extending to November 2027 indicates a long-term incentive structure for the CEO, contingent on continuous service to the company.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing, which is a standard disclosure for insider transactions.

Industry Context

This Form 4 filing details an executive compensation event, specifically an RSU grant, which is a common practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key leadership by aligning their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice in the biotechnology sector, comparable to compensation structures seen at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, where equity awards are a significant component of executive pay.
• The vesting schedule, typically over several years and contingent on continuous service, is also consistent with industry norms designed to promote long-term retention and performance.
• The $0 transaction price for RSUs is standard, as these represent a right to receive shares upon vesting, not a purchase.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with long-term shareholder value through equity ownership.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• 50% of the granted RSUs will vest on November 15, 2026, subject to continuous service.
• The remaining 50% of the granted RSUs will vest on November 15, 2027, subject to continuous service.

Key Dates

Keywords

Replimune Group, REPL, Sushil Patel, Restricted Stock Units, RSU, Insider Trading, Executive Compensation, Form 4, Beneficial Ownership